Agreement will build on Millipore’s leading
position in cell culture supplement market
BILLERICA, MA. March 6, 2024 -- Millipore Corporation (NYSE: MIL), a life science
leader that provides technologies, tools and services for
bioscience research and biopharmaceutical manufacturing, today
announced an agreement with Solabia S.A.S. to distribute
animal-free hydrolysates to its biopharmaceutical customers. Under
the terms of the agreement, Millipore will have exclusive rights to
market and sell all seven of Solabia’s plant-derived
hydrolysates, branded by Millipore under the LucraTone™
family of products, for cell culture media applications throughout
the Americas, the European Economic Community, and the Asia-Pacific
region.
Plant-derived hydrolysates, also
known as plant-derived peptones, are a critical supplement used in
the production of biologic drugs and are typically derived from
soy, wheat, peas, or potatoes. Hydrolysates are a key source of
nutrition for cells and help to stimulate growth and protein
expression during biopharmaceutical manufacturing.
In the past, animal-derived cell
culture supplements have been used to help engineered cells
efficiently produce the proteins that are the basis of biologic
drugs. Today, biopharmaceutical customers are demanding a greater
selection of animal-free supplements to reduce their risk and ease
regulatory concerns. Over the past twelve months, Millipore has
significantly expanded its offering of animal-free supplements for
biopharmaceutical customers.
“Our partnership with Solabia
will enable us to provide customers with a broader range of
animal-free cell culture supplements to optimize their upstream
bioprocessing operations,” said Andrew Bulpin, Ph.D., Vice
President of Millipore’s Upstream Bioprocessing Business
Unit. “In addition to offering customers a stable supply of
animal-free hydrolysates, we are collaborating with Solabia to
launch new, innovative products specifically for the cell culture
market.”
“The cell culture market
represents new and exciting opportunities for peptone applications
and Solabia is pleased to join forces with a recognized leader in
the biopharmaceutical industry,” said Gérard Josset,
President of the Solabia Group. “Together, Solabia’s
manufacturing and Millipore’s expertise can do more for the
cell culture market than either company could do individually, and
customers will benefit from an integrated
solution.”
Solabia has nearly 40 years of
experience and is an ISO-certified global leader in hydrolysate
manufacturing. The agreement between Millipore and Solabia ensures
that biopharmaceutical manufacturers will have a consistent supply
of animal-free hydrolysates for use in manufacturing biologic drugs
and in the development of new cell lines.
Solabia manufactures animal-free
hydrolysates in its Beauvais, France facility, and has invested in
a separate manufacturing operation in Brazil, demonstrating their
commitment to meet customers’ needs for business
continuity.
About Millipore
Millipore (NYSE: MIL) is a Life Science
leader providing cutting-edge technologies, tools, and services for
bioscience research and biopharmaceutical manufacturing. As a
strategic partner, we collaborate with customers to confront the
world’s challenging human health issues. From research to
development to production, our scientific expertise and innovative
solutions help customers tackle their most complex problems and
achieve their goals. Millipore Corporation is an S&P 500
company with more than 6,100 employees in 47 countries worldwide.
For more information, please contact Millipore Tech Service at
1-800-548-7853 or 951-676-8080 or visit www.millipore.com.
SOURCE